不同非甾体消炎药抑制人卵巢癌细胞裸鼠种植瘤的研究  

The Inhibitory Effect of Different Non-Steroidal Anti-Inflammatory Drugs on Xenotransplanted Human Ovarian Tumors

作　　者：王薇 王天舒[2] 王宁 李永梅 湛先保 WANG Wei;WANG Tianshu;WANG Ning;LI Yongmei;ZHAN Xianbao(Department of Oncology,the First Affiliated Hospital of the Second Military Medical University,Shanghai 200433,China;Central Laboratory,Baoshan Branch of Shanghai First People's Hospital,Shanghai Jiaotong University,Shanghai,Shanghai 200940,China)

机构地区：[1]中国人民解放军海军军医大学附属第一医院肿瘤科,上海200433 [2]上海市第一人民医院宝山分院中心实验室,上海200092

出　　处：《肿瘤药学》2018年第3期333-336,共4页Anti-Tumor Pharmacy

摘　　要：目的观察非特异性环氧化酶(COX)抑制剂阿司匹林和选择性COX-2抑制剂美洛昔康在卵巢癌荷瘤裸鼠的抗肿瘤效果。方法选择雌性裸鼠,皮下种植人卵巢癌细胞株OVCAR-3或腹膜内种植人卵巢癌细胞株DISS,经阿司匹林(200μg·mL^(-1))或美洛西康(162μg·mL^(-1))治疗,比较荷瘤小鼠的肿瘤增长和生存期。结果与对照组相比较,阿司匹林和美洛西康治疗组的肿瘤生长受到明显抑制。美洛西康治疗组的肿瘤抑制率优于阿司匹林治疗组(P<0.05)。相较于对照组和阿司匹林治疗组,美洛西康治疗组生存期明显延长,而对照组和阿司匹林治疗组裸鼠的生存期并无明显区别。结论选择性COX-2抑制剂美洛西康在抑制卵巢癌细胞增长和腹水方面优于非选择性COX抑制剂,而且更安全。Objective To investigate the anti-tumor effects of aspirin,non-specific cyclooxygenase(COX)inhibitors,and meloxicam,a selective COX-2 inhibitor,on xenotransplanted ovarian cancer.Methods The female mice xenografted with subcutaneous OVCAR-3 tumors or with intraperitoneal DISS tumors were treated with aspirin(200 ppm in diet,everyday)or meloxicam(162 ppm in diet,everyday).Compare the tumor growth and survival after treatment between them.Results Each of aspirin and meloxicam treatment significantly suppressed the growth of OVCAR-3 tumors xenotransplanted subcutaneously as compared to control.The inhibition rate of OVCAR-3 tumor growth was higher in the meloxicam treatment group than in the aspirin treatment group(P<0.05).Meloxicam treatment significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared to control and aspirin treatment.There was no significant difference in survival between control and aspirin treatment.Conclusion These results indicated that a selective COX-2 inhibitor produced greater anti-tumor effect against ovarian cancer than a nonselective COX inhibitor and that meloxicam may have a potential of leading to a novel therapeutic strategy against ovarian cancer.

关 键 词：非甾体消炎药 选择性COX-2抑制剂 美洛昔康 卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤]